Medical Devices

With a new strategic investor and a star executive on its board, Apreo Health is poised to advance its breakthrough BREATHE Airway Scaffold for severe emphysema.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

The medical device maker posts its 14th straight growth quarter, with soaring profits and a strategic focus on the underserved bronchiectasis market.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

Two neurotech giants are creating an open ecosystem for AI in brain imaging, aiming to speed up diagnostics for epilepsy, tumors, and brain injury.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

From lab breakthroughs to Hollywood advocacy, the 2026 Reeve Summit showcases a powerful, multi-front strategy to cure paralysis and enrich lives today.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

A Belgian firm's new biologic gel for diabetic foot ulcers gets a key FDA green light, offering hope against a leading cause of amputations.

Impulse Biomedical, a Cape Town startup, enters the US market via a Maryland program, bringing a reloadable epi-pen and an ergonomic inhaler sleeve.

Fueled by personal tragedy and backed by tech titans, a new foundation aims to revolutionize lung cancer detection using AI and genetics for non-smokers.

Despite a net loss, Ampco-Pittsburgh posts record results in one segment and a growing backlog, signaling a potential turnaround for the rest of 2026.

The surgical robotics market is set to double by 2030, fueling a high-stakes battle between giants and a critical race for supply chain innovation.

The medtech firm reports a 19% revenue surge and a return to profitability, validating its new pure-play strategy focused on the surgical market.

Medical device firm SI-BONE posts strong Q1 revenue and narrows losses, raising its 2026 outlook on new product momentum and favorable reimbursement news.

United Education Institute's new Houston campus launches with strong government backing, aiming to fill critical skilled trade and healthcare jobs.

A renewed alliance aims to break key supply chain bottlenecks in gene therapy, offering developers faster access to critical, regulatory-ready materials.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

A groundbreaking surgical technique in Gujarat eliminates neck scars, offering new hope and faster recovery for millions with thyroid conditions.

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.